Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.35 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14679403 | 0.89 | FAAH (0.38) | TLR7MAPTLMNACYP2D6CYP1A2 | |
| SCHEMBL10102147 | 0.84 | PTPN1 (0.41) | PTPN1MAPTLMNAHPGDNOX1 | |
| SCHEMBL10102002 | 0.82 | PTPN1 (0.40) | PTPN1MAPTLMNAHPGDNOX1 | |
| SCHEMBL10102020 | 0.78 | L3MBTL1 (0.34) | HDAC3HDAC1HDAC2NCOR2PTPN1 | |
| SCHEMBL10102006 | 0.78 | PTPN1 (0.40) | PTPN1MAPTLMNAHPGDNOX1 | |
| SCHEMBL10107617 | 0.74 | FAAH (0.39) | MAPTLMNAHPGDCYP2D6CYP1A2 | |
| SCHEMBL10101772 | 0.74 | MAPT (0.40) | PTPN1MAPTHPGDNOX1 | |
| SCHEMBL10102104 | 0.73 | ITGB3 (0.36) | PTPN1PPARGMAPTLMNAHPGD | |
| SCHEMBL10107486 | 0.73 | LMNA (0.41) | MAPTLMNACYP2D6CYP1A2CYP3A4 | |
| SCHEMBL10101766 | 0.71 | PTPN1 (0.43) | PTPN1MAPTLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828988-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8367654-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TET1, TET3, HDAC8 | HDAC3 83/4885HDAC1 15/4885HDAC2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.